Ss-20 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-003730-25-NL (EUCTR) | 14/02/2017 | 09/01/2017 | A study to assess the safety and efficacy of a new medicine SBT-020 in patients with Early Stage Huntington’s Disease. | A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease. - SBT-020 in HD | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SBT-020 Product Code: SBT-020 INN or Proposed INN: SBT-020 Other descriptive name: SS-20 | Stealth Bio Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Netherlands |